000756 新华制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.70311.44110.82610.41710.490
总资产报酬率 ROA (%)3.1196.0005.2714.8334.802
投入资产回报率 ROIC (%)3.8957.4226.6316.1135.598

边际利润分析
销售毛利率 (%)25.03029.52427.15427.03730.215
营业利润率 (%)6.4996.5996.3546.4887.035
息税前利润/营业总收入 (%)6.4446.7786.7157.2288.248
净利润/营业总收入 (%)5.7646.2485.6795.5195.780

收益指标分析
经营活动净收益/利润总额(%)104.919106.994102.27591.717102.157
价值变动净收益/利润总额(%)3.1371.7991.7731.9031.363
营业外收支净额/利润总额(%)-1.387-0.356-1.045-1.034-2.635

偿债能力分析
流动比率 (X)1.3921.3331.0941.1011.128
速动比率 (X)0.9360.8050.7110.6900.656
资产负债率 (%)43.04242.36547.37250.20352.188
带息债务/全部投入资本 (%)28.04928.63335.11224.727--
股东权益/带息债务 (%)244.525237.510175.807245.469200.379
股东权益/负债合计 (%)126.464129.703105.39094.21587.090
利息保障倍数 (X)188.50433.57815.7348.9625.917

营运能力分析
应收账款周转天数 (天)32.75832.46634.06228.4940.000
存货周转天数 (天)63.53479.60873.75480.9260.000